Awakn Life Sciences (TSE:AWKN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Awakn Life Sciences has partnered with the University of Nottingham to conduct preclinical trials on a new chemical entity aimed at enhancing mental health treatments. The study, led by Dr. Madeleine King, focuses on the potential of aminoindane to improve social cognition and behaviors, particularly for PTSD. This collaboration marks a significant step in Awakn’s mission to develop innovative therapies for mental health disorders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.